Acurx Pharmaceuticals Inc
General ticker "ACXP" information:
- Sector: Health Care
- Industry: Biotechnology
- Capitalization: $15.5M
Acurx Pharmaceuticals Inc does not follow the US Stock Market performance with the rate: -33.4%.
Estimated limits based on current volatility of 4.8%: low 0.77$, high 0.85$
Factors to consider:
- Current price 62.8% below estimated low
- Earnings for 6 months up through Q2 are below our estimates
Stock Forecast*
* forecast is subjective and experimental, should not be used for any investment decisions
Long term estimates were made for the period from 2023-12-31 to 2025-12-30
- 2023-12-31 to 2024-12-30 estimated range: [2.35$, 5.77$]
- 2024-12-30 to 2025-12-30 estimated range: [2.16$, 5.39$]
Financial Metrics affecting the ACXP estimates:
- Negative: Non-GAAP EPS, $ of -1.15 <= 0.10
- Negative: Operating profit margin, % of -100 <= 1.03
- Negative: Operating cash flow per share per price, % of -17.50 <= 2.35
- Negative: negative Net income
- Positive: Interest expense per share, $ of 0 <= 0
- Negative: Industry operating cash flow per share per price (median), % of -23.87 <= 3.85
Short-term ACXP quotes
Long-term ACXP plot with estimates
Financial data
| YTD | 2021-12-31 | 2022-12-31 | 2023-12-31 |
|---|---|---|---|
| Operating Revenue | $0.00MM | $0.00MM | $0.00MM |
| Operating Expenses | $12.81MM | $12.09MM | $14.58MM |
| Operating Income | $-12.81MM | $-12.09MM | $-14.58MM |
| R&D Expense | $2.03MM | $4.75MM | $6.04MM |
| Income(Loss) | $-12.81MM | $-12.09MM | $-14.58MM |
| Other Income(Loss) | $0.07MM | $0.00MM | $0.00MM |
| Profit(Loss) | $-12.75MM | $-12.09MM | $-14.58MM |
| Stockholders Equity | $12.41MM | $7.32MM | $4.67MM |
| Assets | $13.25MM | $9.38MM | $7.71MM |
| Operating Cash Flow | $-5.01MM | $-7.54MM | $-9.80MM |
| Capital expenditure | $0.00MM | $0.00MM | $0.00MM |
| Financing Cash Flow | $14.80MM | $3.70MM | $8.16MM |
| Earnings Per Share* | $-1.24 | $-1.12 | $-1.15 |
* EPS are Split Adjusted, recent splits may be reflected with a delay.